Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Longeveron ( (LGVN) ) has issued an update.
On March 23, 2026, Longeveron Inc. cancelled a special meeting of stockholders that had been scheduled to take place in 2026, halting the originally planned forum for certain shareholder votes. The company now plans to move the previously proposed reverse stock split to its next regular annual meeting of stockholders, should it determine that such corporate action remains necessary or advisable, signaling a shift in the timing but not necessarily the substance of its capital structure plans.
The most recent analyst rating on (LGVN) stock is a Hold with a $0.97 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.
Spark’s Take on LGVN Stock
According to Spark, TipRanks’ AI Analyst, LGVN is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and cash burn with elevated financing/dilution risk). Offsetting this are constructive technical momentum signals and an earnings-call backdrop with clear clinical catalysts and extended runway from recent financing, though valuation remains difficult to support given negative earnings and no dividend.
To see Spark’s full report on LGVN stock, click here.
More about Longeveron
Longeveron Inc. is a biotechnology company focused on developing cellular therapies, with its operations centered on advanced regenerative medicine approaches. The company targets age-related and life-threatening conditions, positioning itself within the clinical-stage biopharmaceutical sector that serves unmet medical needs in specialized patient populations.
Average Trading Volume: 5,583,312
Technical Sentiment Signal: Sell
Current Market Cap: $22.18M
For an in-depth examination of LGVN stock, go to TipRanks’ Overview page.